AUSTEDO XR: A Beacon of Hope for Tardive Dyskinesia Patients
In recent surveys involving 209 patients diagnosed with tardive dyskinesia (TD), a marked improvement in symptoms was reported by over 94% of participants using AUSTEDO XR (deutetrabenazine) extended-release tablets. This desirable outcome reflects not just physical changes but also a significant enhancement in emotional and social well-being. Patients took to the treatment with great enthusiasm, evidenced by over 89% expressing high satisfaction and 96% wanting to continue their treatment journey.
The Power of AUSTEDO XR
AUSTEDO XR stands out not only for its ability to manage TD symptoms effectively, but also for its convenience. Patients highlighted that more than 96% found it easy to integrate into their daily lives. Teva Pharmaceuticals, known for its commitment to improving healthcare outcomes, unveiled these impactful results during the latest Psych Congress Annual Meeting.
Understanding Tardive Dyskinesia
Tardive dyskinesia is a chronic movement disorder that, unfortunately, affects many individuals undergoing long-term treatment for psychiatric conditions. The condition manifests through uncontrollable movements that can severely impact daily activities, social interactions, and overall quality of life. This is why effective treatment options like AUSTEDO XR are more than just medication; they are a lifeline.
Patient-Centric Focus of Teva Pharmaceuticals
Eric Hughes, MD, PhD, the Executive VP and Chief Medical Officer at Teva, shares a passion for understanding the human aspect behind TD, which includes listening to patients' experiences and continuously innovating therapeutic approaches. This dedication underpins Teva's mission to not just alleviate symptoms but to enhance the overall quality of life for those afflicted.
Survey Insights: A Closer Look
The survey findings are compelling. Almost all participants communicated a significant reduction in their involuntary movements after commencing treatment with AUSTEDO XR—crucially, both long-time users of valbenazine and those who were starting treatment reported similar levels of improvement. Enhanced emotional comfort in social settings was also noted by over 77% of respondents, showcasing the extensive impact of symptom management on personal and social well-being.
Medication Usage and Insights
AUSTEDO XR is not merely another pill; it's a once-daily option formulated to accommodate the complexities of tardive dyskinesia treatment. It was developed as part of a broader line of medications aimed at improving movement disorders, including chorea related to Huntington’s disease. The ease with which patients reported taking AUSTEDO XR further emphasizes Teva's commitment to providing accessible therapies. The pros of adjusting dosage also resonated with patients, evidenced by a striking 82% approval.
Safety and Monitoring
Patient safety remains paramount, and this is particularly true for those treated with AUSTEDO XR. Users must be vigilant for any mood-related changes, as the medication can influence mood stability. Close monitoring by healthcare professionals is recommended, ensuring that the benefits of managing tardive dyskinesia are balanced with understanding the potential mental health impacts of the treatment.
Long-Term Commitment to Patient Health
Teva’s long-standing commitment to healthcare innovation is reflected in their continuous assessment and advancement of treatment efficacy for conditions like tardive dyskinesia. With past safety and effectiveness studies and ongoing reports from patients, AUSTEDO XR has set the stage for future innovations that further enhance the quality of life for those living with this condition.
Frequently Asked Questions
What is AUSTEDO XR?
AUSTEDO XR is an extended-release medication indicated for the treatment of tardive dyskinesia and chorea associated with Huntington's disease, designed for once-daily use.
How effective is AUSTEDO XR?
Surveys indicate that over 94% of patients experience improvement in their symptoms with AUSTEDO XR, reflecting its effectiveness.
Are there any safety concerns with AUSTEDO XR?
While AUSTEDO XR is generally safe, patients should be monitored for mood changes or symptoms of depression, as mental health can be affected.
How satisfied are patients with AUSTEDO XR?
In surveys, over 89% of patients reported being very satisfied with AUSTEDO XR, with most expressing interest in continuing their treatment.
Where can I find more information on AUSTEDO XR?
For more information, including prescribing details and safety information, consult with a healthcare provider or refer to official resources provided by Teva Pharmaceuticals.
